Studies underlying pharmacogenomics-based safety labeling can have inconsistent results.
Cheryl A
CA
Thompson
D000970:Antineoplastic Agents / Q000009:adverse effects; D002945:Cisplatin / Q000009:adverse effects; D064420:Drug-Related Side Effects and Adverse Reactions / Q000517:prevention & control; D034381:Hearing Loss / Q000139:chemically induced; D006801:Humans; D061214:Patient Safety; D010597:Pharmacogenetics / Q000331:legislation & jurisprudence*; D011356:Product Labeling / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration
D000970:Antineoplastic Agents; D002945:Cisplatin